# iCAD

According to OpenAITools.app telemetry verified on 2026-11-11, iCAD (icadmed.com) is an AI platform indexed under AI Medical Diagnosis generating 6.1K monthly visits with a month-over-month traffic delta of +350 (+6.1%). Its primary geographic market is United States (70.9% traffic share), and it operates on a Contact for Pricing pricing model. Top competing alternatives by monthly volume include Lunit (29.18K visits/mo), Pearl (221.16K visits/mo), RapidAI (20.17K visits/mo).

Clinically proven AI that helps radiologists find breast cancer earlier.

## Key Telemetry & Specifications

| Metric | Value |
| :--- | :--- |
| Tool Name | iCAD |
| Handle | icadmed-com |
| Status | active |
| Origin | independent |
| Maintenance | active |
| Official Domain | icadmed.com |
| Website URL | https://icadmed.com |
| Categories | AI Medical Diagnosis, AI Healthcare, AI Image Recognition, AI Detector |
| Pricing Model | Contact for Pricing |
| Monthly Visits | 6,102 |
| MoM Traffic Change | 350 |
| MoM Growth Rate | +6.1% |
| Primary Market | United States |
| Market Share | 70.9% |
| Direct Visits | 1,806 |
| Organic Search Visits | — |
| Social Visits | — |
| Referral Visits | 443 |
| Email Visits | 197 |
| Review Score | 4.4 |
| Saved Count | 0 |
| Supported Platforms | Website |
| Billing Platforms |  |
| Attributes | Features: Website; Pricing: Contact for Pricing |
| Tags | Artificial Intelligence, Cancer Detection, Breast Health, Mammography, Density Assessment, Risk Evaluation, AI-powered Mammograms, Medical Imaging, Healthcare Technology |

## Overview

iCAD is a medical AI company focused on breast health. Its flagship offering, the ProFound Breast Health Suite, pairs cancer detection, density assessment and risk evaluation in one platform so radiology teams can find cancers earlier, standardise density scoring and identify high-risk women who may benefit from tailored screening schedules. The company reports two decades of experience, availability in around 50 countries and more than 40 million mammograms analysed in the last five years.

The clinical argument rests on a familiar problem: a meaningful share of breast cancers are missed in screening, especially in women with dense breast tissue, and traditional risk models are far from perfect. iCAD trains its algorithms on large, diverse mammography datasets and validates them across published clinical studies, with the goal of reducing recalls while catching more invasive disease. Media outlets and an extensive user presence sit behind implementation complexity, including integration with existing workstations and reporting systems.

Since July 2025 iCAD has been part of DeepHealth, the digital health subsidiary of RadNet, which completed its acquisition of the company. That consolidation strengthened a broader imaging AI portfolio, but the breast health products continue to be marketed and supported under the iCAD name. Procurement runs through a demo-and-quote process rather than published price lists, which is typical for clinical AI sold to hospitals and imaging centers.

## Pricing & Plans

Contact for pricing. iCAD quotes per practice based on the modules deployed and screening volume, after a scheduled demo.

## Key Features & Capabilities

- **Cancer detection:** Highlights suspicious lesions in 2D and 3D mammograms so radiologists find more invasive and interval cancers.
- **Density assessment:** Delivers objective, consistent breast density scoring that informs personalised screening decisions.
- **Risk evaluation:** An image-based model that assesses a woman's risk of developing breast cancer before or at her next screening.
- **Clinically proven algorithms:** Four generations of algorithms trained with clinical data from 20M+ images across roughly 130 clinical sites.
- **Deployment flexibility:** Flexible on-site or cloud deployment that fits existing workstations and PACS workflows.

## Primary Use Cases

- **Read screening mammograms faster and more accurately (Breast imaging radiologist):** Add AI marking to 2D and 3D screening reads to catch more invasive and interval cancers.
- **Standardise density reporting (Screening programme lead):** Replace subjective density reads with objective scoring that supports supplemental screening decisions.
- **Identify high-risk patients (Women's health clinic):** Use image-based risk estimates to identify women who may need earlier or additional screening.
- **Integrate AI into existing infrastructure (Imaging IT director):** Push AI results into PACS and reporting systems so reads stay in one workflow.

## Strengths

- Clinically validated across dozens of published studies and large datasets
- Covers detection, density and risk in a single breast health platform
- Available internationally, including FDA clearance, CE marking and Health Canada licensing
- Deploys flexibly and integrates with mainstream workstations and PACS

## Limitations

- No public pricing, so budgeting requires a sales conversation
- Risk module availability is limited outside the US and is investigational there
- Deployment and training require buy-in from radiology IT and reading workflows

## Frequently Asked Questions

### Is iCAD the same as DeepHealth?
iCAD is now part of DeepHealth, following RadNet's acquisition completed in July 2025. The breast health products remain available under the iCAD brand.

### How much does it cost?
Pricing is not published publicly. Radiology practices and health systems request a demo and receive a quote based on the modules and screening volume.

### Is ProFound AI Risk available everywhere?
No. ProFound AI Risk is CE marked and Health Canada licensed, but it is not FDA cleared and is only available in the US for investigational use.

### Does it work with existing mammography equipment?
Yes. The suite supports 2D and 3D mammography and multiple output formats, so it can integrate with common workstations and PACS environments.

### What is iCAD's monthly traffic and growth trend?
iCAD currently receives 6.1K monthly visits, with a month-over-month traffic change of +350 (+6.1% growth rate). Its primary source market is United States (70.9% share), including 1.81K direct visits/mo and — organic search visits/mo.

### Is iCAD free? What is its pricing model?
iCAD operates on a Contact for Pricing pricing model. Contact for pricing. iCAD quotes per practice based on the modules deployed and screening volume, after a scheduled demo. Supported billing and checkout platforms include: not listed.

### What are the best iCAD alternatives in 2026?
Based on OpenAITools.app category traffic and feature fit, the top five alternatives to iCAD are: 1. Lunit (29.18K visits/mo); 2. Pearl (221.16K visits/mo); 3. RapidAI (20.17K visits/mo); 4. Ibex Medical Analytics (9.12K visits/mo); 5. Oatmeal Health (40.26K visits/mo).

### Which platforms and core AI capabilities does iCAD support?
iCAD is classified under AI Medical Diagnosis, AI Healthcare, AI Image Recognition, AI Detector, supports the following platforms: Website, and its core capability tags include: Artificial Intelligence, Cancer Detection, Breast Health, Mammography, Density Assessment, Risk Evaluation.

## Alternatives

| Tool Name | Monthly Visits | Pricing Model | Compare |
| :--- | :--- | :--- | :--- |
| [Lunit](https://openaitools.app/tool/lunit) | 29,181 | Contact for Pricing | [Compare](https://openaitools.app/compare/icadmed-com-vs-lunit) |
| [Pearl](https://openaitools.app/tool/hellopearl-com) | 221,155 | Contact for Pricing | [Compare](https://openaitools.app/compare/hellopearl-com-vs-icadmed-com) |
| [RapidAI](https://openaitools.app/tool/rapidai-com) | 20,172 | Contact for Pricing | [Compare](https://openaitools.app/compare/icadmed-com-vs-rapidai-com) |
| [Ibex Medical Analytics](https://openaitools.app/tool/ibex-ai-com) | 9,117 | Contact for Pricing | [Compare](https://openaitools.app/compare/ibex-ai-com-vs-icadmed-com) |
| [Oatmeal Health](https://openaitools.app/tool/oatmeal-health) | 40,264 | Contact for Pricing | [Compare](https://openaitools.app/compare/icadmed-com-vs-oatmeal-health) |
| [CT Read](https://openaitools.app/tool/ct-read) | 103,157 | Paid | [Compare](https://openaitools.app/compare/ct-read-vs-icadmed-com) |
| [Overjet](https://openaitools.app/tool/overjet-ai) | 256,150 | Contact for Pricing | [Compare](https://openaitools.app/compare/icadmed-com-vs-overjet-ai) |
| [coronarography.ai](https://openaitools.app/tool/coronarography-ai) | 455 | Free | [Compare](https://openaitools.app/compare/coronarography-ai-vs-icadmed-com) |
| [Empirical Health](https://openaitools.app/tool/empirical-health) | 70,517 | Paid | [Compare](https://openaitools.app/compare/empirical-health-vs-icadmed-com) |
| [Dr.Oracle](https://openaitools.app/tool/dr-oracle) | 723,847 | Free Trial | [Compare](https://openaitools.app/compare/dr-oracle-vs-icadmed-com) |
| [Idoven](https://openaitools.app/tool/idoven-ai) | 5,625 | Contact for Pricing | [Compare](https://openaitools.app/compare/icadmed-com-vs-idoven-ai) |
| [MD.ai](https://openaitools.app/tool/md-ai) | 6,650 | Contact for Pricing | [Compare](https://openaitools.app/compare/icadmed-com-vs-md-ai) |

---
Source: https://openaitools.app/tool/icadmed-com